-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: September 2010
Don’t Be Afraid of “Frankenfish”
The Wall Street Journal ran on September 23, 2010, an op-ed authored by BIO President and CEO Jim Greenwood about FDA’s pending approval of a genetically engineered salmon. This salmon can help meet the growing demand for protein-rich food without depleting wild fish stocks. Right now, the government is deciding whether it’s safe for us to eat genetically engineered salmon. The fish, called AquAdvantage, is being developed by a Massachusetts biotech firm and is in Read More >
Science Advisory Board Has Rigorous Discussion on GE Salmon
FDA Approval Could Pave the Way for Future Science-based Technologies As part of the U.S. Food and Drug Administration’s rigorous, scientific regulatory review governing genetically engineered (GE) animal technologies, the FDA’s Veterinary Medicine Advisory Committee (VMAC) hosted a rigorous discussion about a GE salmon on September 19-21. The AquAdvantage® Salmon is genetically engineered to reach its market weight in half the time of conventionally raised salmon thus contributing to more sustainable aquaculture systems. It was Read More >
Icons: What Do They Mean?
We are pleased to announce the release of one of our newest software improvements to the BIO One-on-One Partnering System. I’m sure most of you have noticed the little gold medallions marking the names of several of the companies in the 1×1 system for the 2010 BIO Investor Forum. They denote those companies which are Presenters (P), BIO Members (B), BIO Board Members (M), and Conference Sponsor (S). We continue to look for ways to Read More >
IPO update: 28 IPOs, 24 on Deck
The number of IPOs slowed during the summer, but the queue has been filling nicely. Fifteen more biotechs have filed to go public in the last month and a half, bringing the total to 24 globally. The two US IPOs this summer were from NuPATH and Trius. Again, we saw a reduction in the amount planned vs actually raised for these IPOs. On average, US biotechs have raised an amount 28% below what is first Read More >
Therapeutic Discovery Program Is a Shot in the Arm for Small Biotechs
Innovation is one of the things Americans do best and when it comes to creating new therapies, it’s also a key to job growth, strong small businesses, and our industry’s ability to address the needs of patients suffering from debilitating diseases such as cancer, HIV/AIDS and Alzheimer’s. The recently implemented Therapeutic Discovery Project Program offers a tax credit to small biotechnology companies on the cusp of discovering cutting-edge treatments and technologies that will have a Read More >
